CYP17 5'-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case–control study

Table 3 Association between CYP17 genetic polymorphisms and premenopausal breast cancer risk by parity in Germany

CYP17 genotype	Cases, no. (%) (n = 527)	Controls, no. (%) (n = 904)	Age-adjusted OR (95% CI)^a	Multivariate-adjused OR (95% CI)^b
All subjects^c
A1/A1	180 (34.2)	323 (35.7)	1.00	1.00
A1/A2	244 (46.2)	424 (46.9)	1.02 (0.80–1.31)	1.04 (0.81–1.34)
A2/A2	103 (19.6)	157 (17.4)	1.18 (0.87–1.61)	1.23 (0.89–1.69)
Trend test P			0.34	0.24
Parous women^d
A1/A1	139 (34.5)	253 (35.9)	1.00	1.00
A1/A2	189 (46.9)	330 (46.8)	1.02 (0.78–1.35)	1.04 (0.78–1.37)
A2/A2	75 (18.6)	122 (17.3)	1.13 (0.79–1.61)	1.14 (0.79–1.65)
Trend test P			0.54	0.50
Nulliparous women
A1/A1	41 (33.0)	70 (35.2)	1.00	1.00
A1/A2	55 (44.4)	94 (47.2)	1.23 (0.72–2.07)	1.31 (0.74–2.32)
A2/A2	28 (22.6)	35 (17.6)	1.74 (0.90–3.38)	2.12 (1.04–4.32)
Trend test P			0.11	0.04

^aAge-adjusted odds ratio (OR) and 95% confidence interval (CI). ^bMultivariate-adjusted OR and 95% CI. Adjusted for age at menarche in years (≤ 12, 13 to 14, 15+); total months of breastfeeding (0, 1 to 12, >12); alcohol consumption (0, 1–18, >18 g/day); current body mass index as continuous variable; educational level (low, middle, high); and family history of breast cancer in first-degree relative (no, yes); oral contraceptive use (no, yes). ^cAlso adjusted for parity (0, 1 to 2 births, 3+ births). ^dAlso adjusted for age at first full-term pregnancy (<25, ≥ 25 years). P for interaction = 0.87.

ISSN: 1465-542X